Hopp til innhold
NHI.no
Annonse

Hypereosinofile syndromer: Behandling

Innhold i artikkelen

Symptomfrie pasienter med uttalt eosinofili kan ha et godartet sykdomsforløp og behøver ingen behandling. Motsatt kan pasienter med alvorlig hypereosinofilt syndrom ha en ekstremt aggressiv sykdom med høy dødelighet om de ikke behandles. Beslutningen om å behandle baserer seg således på sykdomsbildet, laboratoriefunnene og kromosomanalysene.

Annonse

Aktuelle medikamenter ved hypereosinofile syndromer er kortison, biologiske medisiner (monoklonale antistoffer), tyrosinkinase-hemmere (imatinib), ciklosporin og kjemoterapeutika.

Ved hjertesykdom kan det bli aktuelt å operere for å reparere skadete hjerteklaffer, fjerne skadet hjertemuskulatur, eventuelt fjerne blodpropper.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Hypereosinofile syndromer . Referanselisten for dette dokumentet vises nedenfor

  1. Roufosse F, Klion AD, Weller PF. Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis. UpToDate, last updated Apr 06, 2020. www.uptodate.com
  2. Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130:607. PubMed
  3. Klion AD, How I treat hypereosinophilic syndromes. Blood 2009;114(18): 3736-41. www.ncbi.nlm.nih.gov
  4. Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27: 333. PubMed
  5. Hasselbalch HC, Larsen EP, Gerlach Øgard C. Hypereosinofilt syndrom. Lægehåndbogen, sist oppdatert 30.10.2018.
  6. Ackerman, SJ, Bochner, BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am 2007; 27: 357. PubMed
  7. Andersen CL, Vestergaard H, Nørgaard P, et al. Eosinofili - en oversigt med præsentation af nye aspekter vedrørende patogenese, sygdomsklassifikation og behandling. Ugeskrift for Læger 2009;171(45): 3256-62. PubMed
  8. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27: 389. PubMed
  9. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124:1319. PubMed
  10. Ogbogu, PU, Rosing, DR, Horne MK, 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27: 457. PubMed
  11. Plastiras SC, Economopoulos N, Kelekis NL, Tzelepis GE. Magnetic resonance imaging of the heart in a patient with hypereosinophilic syndrome. Am J Med 2006; 119: 130. PubMed
  12. Chaine G, Davies J, Kohner EM, et al. Ophthalmologic abnormalities in the hypereosinophilic syndrome. Ophthalmology 1982; 89: 1348. PubMed
  13. Roufosse F, Klion AD, Weller PF. Hypereosinophilic syndromes: Treatment. UpToDate, last updated Apr 07, 2019. UpToDate
  14. Dispenza MC, Bochner BS. Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes. Curr Hematol Malig Rep. 2018;13(3):191‐201. doi:10.1007/s11899-018-0448-8 DOI
  15. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 2004; 77: 82. PubMed
  16. Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris) 1989; 140: 253. PubMed
Annonse
Annonse